Clinical response to imatinib mesylate in recurrent and metastatic gastrointestinal stromal tumors

被引：0
|
作者：
Villalobos, R. [1 ]
Hernandez, G. [1 ]
Martinez-Prieto, M. [1 ]
Silva, A. [1 ]
机构：
[1] UMAE Hosp Oncol CMN Siglo XXI, Mexico City, DF, Mexico
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20528
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan
    Yeh, Chun-Nan
    Chen, Yen-Yang
    Tseng, Jeng-Hwei
    Chen, Jen-Shi
    Chen, Tsung-Wen
    Tsai, Chun-Yi
    Cheng, Chi-Tung
    Jan, Yi-Yin
    Chen, Miin-Fu
    TRANSLATIONAL ONCOLOGY, 2011, 4 (06): : 328 - 335
  • [2] Clinical Significance of Pathological Complete Response in Patients with Metastatic Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment - Lessons Learned
    Cheng, Chi-Tung
    Tsai, Chun-Yi
    Yeh, Chun-Nan
    Chiang, Kun-Chun
    Chen, Yen-Yang
    Wang, Shang-Yu
    Chen, Tsung-Wen
    Tseng, Jeng-Hwei
    Jung, Shih-Ming
    Chen, Tse-Ching
    Yeh, Ta-Sen
    ANTICANCER RESEARCH, 2014, 34 (11) : 6617 - 6625
  • [3] Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
    Dagher, R
    Cohen, M
    Williams, G
    Rothmann, M
    Gobburu, J
    Robbie, G
    Rahman, A
    Chen, G
    Staten, A
    Griebel, D
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3034 - 3038
  • [4] Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty
    Yildiz, Ibrahim
    Mandel, Nil M.
    Demir, Gokhan
    Ozguroglu, Mustafa
    Toptas, Tayfur
    Buyukunal, Evin
    Serdengecti, Suheyla
    ANNALS OF ONCOLOGY, 2006, 17 : 164 - 164
  • [5] Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Farrell, Ann
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (02): : 174 - 180
  • [6] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07): : 472 - 480
  • [7] Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors
    Han, Hui
    Yu, Yang-yang
    Wang, Yu-hong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (05) : S80 - S83
  • [8] Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
    Casali, PG
    Bertulli, R
    Fumagalli, E
    Coco, P
    Grosso, F
    Stacchiotti, S
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 55 - 58
  • [9] Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
    Gauden, Ruth
    Gauden, Stan
    CASE REPORTS IN ONCOLOGY, 2011, 4 (01): : 204 - 210
  • [10] The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors
    DeCaprio, James A.
    Duensing, Anette
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (04) : 415 - 421
12345